

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 April 2001 (19.04.2001)

PCT

(10) International Publication Number
WO 01/26654 A1

- (51) International Patent Classification⁷: A61K 31/404; C07D 209/14
- (21) International Application Number: PCT/US00/27591
- (22) International Filing Date: 6 October 2000 (06.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/158,529 8 October 1999 (08.10.1999) US
- (71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): MILLER, William, H. [US/US]; 132 Chinaberry Lane, Collegeville, PA 19426 (US). NEWLANDER, Kenneth, A. [US/US]; 911 Sage Road, West Chester, PA 19382 (US). SEEFELD, Mark, A. [US/US]; 2015 Waterfall Circle, Collegeville, PA 19426 (US).
- (74) Agents: MCCARTHY, Mary, E. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).
- (81) Designated States (national): AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FAB I INHIBITORS



(57) Abstract: Compounds of formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections wherein: R¹ is C₁₋₄alkyl; R² is C₁₋₄alkyl; R³ is -C₁₋₄alkyl, -C₀₋₄alkyl-Ar or -C₀₋₄alkyl-Het; R⁴ is -C₁₋₄alkyl, -(CH₂)₁₋₄OH, -OC₁₋₄alkyl, -SC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -C₀₋₄alkyl-Ar, -C₀₋₄alkyl-C₃₋₆cycloalkyl, -CH(OH)-CH₂-R* or

-(CH₂)₁₋₃SO₂Ar; R* is C₁₋₄alkyl, Ar or Het; X is H, C₁₋₄alkyl, OR', SR', CN, N(R')₂, CH₂N(R')₂, NO₂, CF₃, CO₂R', CON(R')₂, COR', NR'C(O)R', F, Cl, Br, I, or -S(O)₂CF₃; R' is H, C₁₋₆alkyl or -C₀₋₆alkyl-Ar; and r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.

TITLE

Fab I Inhibitors

FIELD OF THE INVENTION

- 5 This invention relates to pharmaceutically active compounds which inhibit Fab I and are useful for the treatment of bacterial infections.

BACKGROUND OF THE INVENTION

- 10 While the overall pathway of saturated fatty acid biosynthesis is similar in all organisms, the fatty acid synthase (FAS) systems vary considerably with respect to their structural organization. Vertebrates and yeast possess a FAS in which all the enzymatic activities are encoded on one or two polypeptide chains, respectively, and the acyl carrier protein (ACP) is an integral part of the complex. In contrast, in bacterial FAS, each of the reactions is catalyzed by a distinct, mono-functional enzyme and the ACP is a discrete
- 15 protein. Therefore, there is considerable potential for the selective inhibition of the bacterial system by antibacterial agents.

- Fab I (previously designated EnvM) functions as an enoyl-ACP reductase (Bergler, et al, (1994), *J.Biol.Chem.* 269, 5493-5496) in the final step of the four reactions involved in each cycle of bacterial fatty acid biosynthesis. In this pathway, the first step is catalyzed
- 20 by β -ketoacyl-ACP synthase, which condenses malonyl-ACP with acetyl-CoA (FabH, synthase III). In subsequent rounds, malonyl-ACP is condensed with the growing-chain acyl-ACP (FabB and FabF, synthases I and II, respectively). The second step in the elongation cycle is ketoester reduction by NADPH-dependent β -ketoacyl-ACP reductase (FabG). Subsequent dehydration by β -hydroxyacyl-ACP dehydrase (either FabA or FabZ)
- 25 leads to trans-2-enoyl-ACP, which in turn is converted to acyl-ACP by NADH-dependent enoyl-ACP reductase (Fab I). Further rounds of this cycle, adding two carbon atoms per cycle, eventually lead to palmitoyl-ACP (16C), where upon the cycle is stopped largely due to feedback inhibition of Fab I by palmitoyl-ACP (Heath, et al, (1996), *J.Biol.Chem.* 271, 1833-1836). Thus, Fab I is a major biosynthetic enzyme and is a key regulatory point in the
- 30 overall synthetic pathway of bacterial fatty acid biosynthesis. Therefore, Fab I is an ideal target for antibacterial intervention.

- Studies have shown that diazaborine antibiotics inhibit fatty acid, phospholipid and lipopolysaccharide (LPS) biosynthesis and that the antibacterial target of these compounds is Fab I. For example, derivative 2b18 from Grassberger, et al (1984) *J. Med Chem* 27 947-
- 35 953 has been reported to be a non-competitive inhibitor of Fab I (Bergler, et al, (1994), *J.Biol.Chem.* 269, 5493-5496). Also, plasmids containing the Fab I gene from diazaborine resistant *S. typhimurium* conferred diazaborine resistance in *E.coli* (Turnowsky, et al,

(1989), *J. Bacteriol.*, 171, 6555-6565). Furthermore, inhibition of Fab I either by diazaborine or by raising the temperature in a Fab I temperature sensitive mutant is lethal. These results demonstrate that Fab I is essential to the survival of the organism (Bergler, et al, (1994), *J. Biol. Chem.* 269, 5493-5496).

- 5 Recent studies have shown that Fab I is also the target for the broad spectrum antibacterial agent triclosan (McMurry, et al, (1998) *Nature* 394, 531-532). A crystal structure of the *E. Coli* Fab I complexed with NAD and triclosan shows that triclosan acts as a site-directed, very potent inhibitor of Fab I by mimicking its natural substrate (Levy, et al, (1999) *Nature* 398, 383-384). Ward, et al ((1999) *Biochem.* 38, 12514-12525) have
- 10 shown that there is no evidence for the formation of a covalent complex between Fab I and triclosan, which would be analogous to the diazaborines; triclosan differs from these compounds in that it is a reversible inhibitor of Fab I. The structural data for the complex of Fab I with NAD and triclosan provides important information about Fab I as a therapeutic target.
- 15 Importantly, it has now been discovered that certain compounds are Fab I inhibitors and have antibacterial activity, and, therefore, may be useful for the treatment of bacterial infections in mammals, particularly in man.

SUMMARY OF THE INVENTION


- 20 This invention comprises compounds of the formula (I), as described hereinafter, which inhibit Fab I and are useful in the treatment of bacterial infections.

This invention is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier.

- This invention is also a method of treating bacterial infections by inhibiting Fab I.
- 25 In a particular aspect, the compounds of this invention are useful as antibacterial agents.

DETAILED DESCRIPTION

This invention comprises compounds of formula (I):



(I)



wherein:

- R^1 is C_{1-4} alkyl;
 R^2 is C_{1-4} alkyl;
 R^3 is $-C_{1-4}$ alkyl, $-C_{0-4}$ alkyl-Ar or $-C_{0-4}$ alkyl-Het;
 R^4 is $-C_{1-4}$ alkyl, $-(CH_2)_{1-4}OH$, $-OC_{1-4}$ alkyl, $-SC_{1-4}$ alkyl, $-N(C_{1-4}alkyl)_2$,
 5 $-C_{0-4}alkyl-Ar$, $-C_{0-4}alkyl-Het$, $-C_{0-4}alkyl-C_3-6cycloalkyl$, $-CH(OH)-CH_2-R^*$ or
 $-(CH_2)_{1-3}SO_2Ar$;
 R^* is C_{1-4} alkyl, Ar or Het;
 X is H, $C_{1-4}alkyl$, OR' , SR' , CN , $N(R')_2$, $CH_2N(R')_2$, NO_2 , CF_3 , CO_2R' ,
 $CON(R')_2$, COR' , $NR'C(O)R'$, F, Cl, Br, I, or $-S(O)_rCF_3$;
 10 R' is H, $C_{1-6}alkyl$ or $-C_{0-6}alkyl-Ar$; and
 r is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

- Also included in this invention are pharmaceutically acceptable addition salts and
 complexes of the compounds of this invention. In cases wherein the compounds of this
 15 invention may have one or more chiral centers, unless specified, this invention includes
 each unique racemic compound, as well as each unique nonracemic compound.


In cases in which compounds have unsaturated carbon-carbon double bonds, both
 the cis (Z) and trans (E) isomers are within the scope of this invention. In cases wherein

- compounds may exist in tautomeric forms, such as keto-enol tautomers, such as 
 20 and , each tautomeric form is contemplated as being included within this invention,
 whether existing in equilibrium or locked in one form by appropriate substitution with R' .
 The meaning of any substituent at any one occurrence is independent of its meaning, or any
 other substituent's meaning, at any other occurrence.

- Also included in this invention are prodrugs of the compounds of this invention.
 25 Prodrugs are considered to be any covalently bonded carriers which release the active
 parent drug according to formula (I) *in vivo*.

- The compounds of formula (I) inhibit Fab I. Inhibition of this enzyme is useful in
 the treatment of bacterial infections. Also, the compounds of this invention may be useful
 as antifungal agents. Additionally, the compounds may be useful in combination with
 30 known antibiotics.

With respect to formula (I), this invention preferably includes compounds of
 formula (Ia):



(Ia)

in which R^3 and R^4 are as defined for formula (I) compounds.

Suitably, with respect to formula (I), R^3 is $-C_{1-4}$ alkyl or $-C_{0-2}$ alkyl-Ph and R^4 is
 5 $-C_{1-4}$ alkyl, $-CH_2OH$, $-OC_{1-4}$ alkyl, $-C_{0-2}$ alkyl-Ph, $-C_{0-2}$ alkyl- C_{3-6} cycloalkyl, $-CH(OH)-CH_2-R^*$ or $-(CH_2)_2SO_2Ph$, in which R^* is as defined for formula (I) compounds.

Representative of the novel compounds of this invention are the following:

- 10 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-methylacetamide;
 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-(2-phenylethyl)acetamide;
 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-hydroxy-4-methyl-N-methylpentanamide;
 15 {4-amino-3-[(ethoxy-N-methylcarbonylamino)methyl]phenyl}-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide;
 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-hydroxy-N-methylacetamide;
 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-3-yl)methyl]carbamoyl}phenyl)methyl]-N-methylacetamide;
 20 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-phenylacetamide;
 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-hydroxy-3-indol-3-yl-N-methylpropanamide;
 25 (4-amino-3-[(4-hydroxyphenyl)-N-methylcarbonylamino]methyl]phenyl)-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide;
 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-methyl-3-(phenylsulfonyl)propanamide; and
 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-cyclopentyl-N-methylacetamide;
 30 or a pharmaceutically acceptable salt thereof.

Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of this invention. In general, the amino acid

abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described in *Eur. J. Biochem.*, 158, 9 (1984).

C₁₋₄alkyl as applied herein means an optionally substituted alkyl group of 1 to 4 carbon atoms, and includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl.

- 5 C₁₋₆alkyl additionally includes pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof. C₀₋₄alkyl and C₀₋₆alkyl additionally indicates that no alkyl group need be present (*e.g.*, that a covalent bond is present).

- Any C₁₋₄alkyl or C₁₋₆alkyl may be optionally substituted with the group R^x, which may be on any carbon atom that results in a stable structure and is available by conventional synthetic techniques. Suitable groups for R^x are C₁₋₄alkyl, OR', SR', CN, N(R')₂, CH₂N(R')₂, -NO₂, -CF₃, -CO₂R', -CON(R')₂, -COR', -NR'C(O)R', F, Cl, Br, I, or -S(O)_rCF₃, wherein R' and r are as defined for formula (I) compounds.

Halogen or halo means F, Cl, Br, and I.

- Ar, or aryl, as applied herein, means phenyl or naphthyl, or phenyl or naphthyl substituted by one to three substituents, such as those defined above for alkyl, or substituted by methylenedioxy.


- Het, or heterocycle, indicates an optionally substituted five or six membered monocyclic ring, or a nine or ten-membered bicyclic ring containing one to three heteroatoms chosen from the group of nitrogen, oxygen and sulfur, which are stable and available by conventional chemical synthesis. Illustrative heterocycles are benzofuryl, benzimidazolyl, benzopyranyl, benzothienyl, furyl, imidazolyl, indolyl, morpholinyl, piperidinyl, piperazinyl, pyrrolyl, pyrrolidinyl, tetrahydropyridinyl, pyridinyl, thiazolyl, thienyl, quinolinyl, isoquinolinyl, and tetra- and perhydro- quinolinyl and isoquinolinyl. Any accessible combination of up to three substituents on the Het ring, such as those defined above for alkyl, that are available by chemical synthesis and are stable are within the scope of this invention.

- Certain radical groups are abbreviated herein. t-Bu refers to the tertiary butyl radical, Boc refers to the t-butyloxycarbonyl radical. Fmoc refers to the fluorenylmethoxycarbonyl radical, Ph refers to the phenyl radical, Cbz refers to the benzyloxycarbonyl radical, Bn refers to the benzyl radical. Me refers to methyl, Et refers to ethyl, Ac refers to acetyl, Alk refers to C₁₋₄alkyl, Nph refers to 1- or 2-naphthyl and cHex refers to cyclohexyl. Tet refers to 5-tetrazolyl.

- Certain reagents are abbreviated herein. DCC refers to dicyclohexylcarbodiimide, DMAP refers to dimethylaminopyridine, EDC refers to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, hydrochloride, HOBt refers to 1-hydroxybenzotriazole. THF refers to tetrahydrofuran, DIEA refers to diisopropylethylamine, DEAD refers to diethyl azodicarboxylate, PPh₃ refers to triphenylphosphine, DIAD refers to diisopropyl

- azodicarboxylate, DME refers to dimethoxyethane, DMF refers to dimethylformamide, NBS refers to N-bromosuccinimide, Pd/C refers to a palladium on carbon catalyst, PPA refers to polyphosphoric acid, DPPA refers to diphenylphosphoryl azide, BOP refers to benzotriazol-1-yloxy-tris(dimethyl-amino)phosphonium hexafluorophosphate, HF refers to hydrofluoric acid, TEA refers to triethylamine, TFA refers to trifluoroacetic acid, PCC refers to pyridinium chlorochromate.


Generally, the compounds of formula (I) are prepared by reacting a compound of formula (II) with a compound of formula (III):



wherein R^1 , R^2 , R^3 , R^4 and X are as defined in formula (I), with any reactive functional groups protected, in the presence of EDC and HOBT;

- and thereafter removing any protecting groups, and optionally forming a pharmaceutically acceptable salt.

In particular, compounds of formula (I) are prepared by the general methods described in Scheme I.

Scheme I

- 5 Reagents and conditions: (a) PhSO_2Cl , pyridine, *t*-BuOH; (b) N-bromosuccinamide, benzoyl peroxide, CH_2Cl_2 ; (c) 40% CH_3NH_2 in H_2O ; (d) $(\text{CH}_3\text{CO})_2\text{O}$, $(i\text{-Pr})_2\text{NEt}$, CH_2Cl_2 ; (e) H_2 , 10% Pd/C, MeOH; (f) TFA, CH_2Cl_2 ; (g) 1-methyl-2-(methylaminomethyl)indole, EDC, HOBT · H_2O , $(i\text{-Pr})_2\text{NEt}$, DMF.

- 10 Commercially available 3-methyl-4-nitrobenzoic acid (**I-1**) is protected at the carboxylic acid functionality with a suitable protecting group, for instance a tertiary butyl (*t*-Bu) group, to afford **I-2**. The use of protecting groups to mask reactive functionality is well-known to those of skill in the art, and other protecting groups are listed in standard reference volumes, such as Greene, "Protective Groups in Organic Synthesis" (published by
- 15 Wiley-Interscience). The benzylic position is brominated under radical conditions using N-bromosuccinamide (NBS) and the radical initiator benzoyl peroxide affording **I-3**. Halogenation of reactive positions, such as the benzylic position of **I-2**, is well known. Nucleophilic substitution of the bromide is accomplished with an excess of aqueous methyl amine, for instance 40% methylamine in water, providing the benzyl amine **I-4**. Acylation

of the pendent nitrogen is accomplished with a suitable acylating reagent such as an acyl halide, or an acid anhydride, to afford N-acyl-substituted derivatives. For example, the benzyl nitrogen can be acylated with acetic anhydride, to afford the amide derivative I-5. The aryl nitro compound I-5 is converted under hydrogenation conditions, in the presence of a catalytic amount of palladium metal on activated carbon (Pd/C), to the amine I-6. Aromatic nitro groups can be reduced by a number of methods involving the use of metals and example procedures can be found in standard chemistry texts such as, "Reductions in Organic Chemistry" published by the (American Chemical Society). The *t*-butyl ester is removed to reveal the carboxylic acid functionality with a suitable acid reagent such as trifluoroacetic acid (TFA) to give I-7. Other standard methods for removal of a *t*-butyl protecting group are described by Greene (see above). The carboxylic acid derivative is then converted to amide I-8 by reaction with an activating agent and a suitable amine species. For example, acid I-7 is converted to an activated form by reaction with EDC and HOBT, and the activated form is subsequently reacted with amine [1-methyl-2-(methylaminomethyl)indole] in a suitable solvent such as DMF, CH₂Cl₂, or CH₃CN. Depending on whether acid neutralization is required, an added base, such as triethylamine (Et₃N), diisopropylethylamine ((i-Pr)₂NEt), or pyridine, may be used.

Many additional methods for converting a carboxylic acid to an amide are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I - VI (published by Wiley-Interscience), or Bodansky, "The Practice of Peptide Synthesis" (published by Springer-Verlag), which are incorporated herein by reference.

Amide coupling reagents as used herein denote reagents which may be used to form peptide bonds. Typical coupling methods employ carbodiimides, activated anhydrides and esters and acyl halides. Reagents such as EDC, DCC, DPPA, PPA, BOP reagent, HOBT, N-hydroxysuccinimide and oxalyl chloride are typical.

Typically, the amine is coupled via its free amino group to an appropriate carboxylic acid substrate using a suitable carbodiimide coupling agent, such as N,N'-dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole (HOBT) and dimethylamino pyridine (DMAP). Other methods, such as the formation of activated esters, anhydrides or acid halides, of the free carboxyl of a suitably protected acid substrate, and subsequent reaction with the free amine, optionally in the presence of a base, are also suitable. For example, a benzoic acid is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran (THF), in the presence of a base, such as N-methylmorpholine, DMAP or a trialkylamine, with isobutyl chloroformate to form the "activated anhydride", which is subsequently reacted with the free amine.

Acid addition salts of the compounds are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable. Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li^+ , Na^+ , K^+ , Ca^{++} , Mg^{++} and NH_4^+ are specific examples of cations present in pharmaceutically acceptable salts.

This invention also provides a pharmaceutical composition which comprises a compound according to formula (I) and a pharmaceutically acceptable carrier. Accordingly, the compounds of formula (I) may be used in the manufacture of a medicament. Pharmaceutical compositions of the compounds of formula (I) prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.

Alternately, these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. Liquid carriers include syrup, peanut oil, olive oil, saline and water. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

For rectal administration, the compounds of this invention may also be combined with excipients, such as cocoa butter, glycerin, gelatin or polyethylene glycols, and molded into a suppository.

For topical administration, the compounds of this invention may be combined with diluents to take the form of ointments, gels, pastes, creams, powders or sprays. The compositions which are ointments, gels, pastes or creams contain diluents, for example, animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures of these substances. The compositions which are powders or sprays contain diluents, for example, lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Additionally, for topical ophthalmologic administration, the typical carriers are water, mixtures of water and water miscible solvents, such as lower alkanols or vegetable oils, and water-soluble non-toxic polymers, for example cellulose derivatives, such as methyl cellulose.

The compounds described herein are inhibitors of Fab I, and are useful for treating bacterial infections. For instance, these compounds are useful for the treatment of bacterial infections, such as, for example, infections of upper respiratory tract (e.g. otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g. empyema, lung abscess), cardiac (e.g. infective endocarditis), gastrointestinal (e.g. secretory diarrhoea, splenic abscess, retroperitoneal abscess), CNS (e.g. cerebral abscess), eye (e.g. blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, dacryocystitis), kidney and urinary tract (e.g. epididymitis, intrarenal and perinephric abscess, toxic shock syndrome), skin (e.g. impetigo, folliculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis), and bone and joint (e.g. septic arthritis, osteomyelitis). Also, the compounds of this invention may be useful as antifungal agents. Additionally, the compounds may be useful in combination with known antibiotics.

The compounds of this invention are administered to the patient, in a manner such that the concentration of drug is sufficient to treat bacterial infections. The pharmaceutical composition containing the compound is administered at an oral dose of between about 10 mg to about 1000 mg, taken once or several times daily, in a manner consistent with the condition of the patient. Preferably, the oral dose would be about 50 mg to about 500 mg, although the dose may be varied depending upon the age, body weight and symptoms of the patient. For acute therapy, parenteral administration is preferred. An intravenous infusion of the compound of formula (I) in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful. The precise level and method by which the compounds are administered is readily determined by one skilled in the art.

The compounds may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.

Cloning of *S. aureus* FabI:

5 The *fabI* gene was cloned from the chromosomal DNA of *S. aureus* strain WCUH29 using the polymerase chain reaction. Amplification was performed using *Taq* DNA polymerase (BRL) and the following primers: 5'-
CGCCTCGAGATGTTAAATCTTGAAAACAAAACATATGTC-3' and 5'-
10 CGCGGATCCAATCAAGTCAGGTGAAATATCCA-3' (*Xho*I and *Bam*HI sites underlined). The resulting fragment was then digested with *Xho*I and *Bam*HI and ligated into *Xho*I- and *Bam*HI-digested expression vector pET-16b (Novagen), producing pET-His₁₀-*fabI*. The gene sequence of *fabI* was confirmed by automated cycle sequencing using an Applied Biosystems model 377 machine. The untagged version of pET-*fabI* was
15 constructed by digesting pET-His₁₀-*fabI* with *Nco*I and *Nde*I to remove a 97 bp fragment encoding the His 10 tag, the factor Xa cleavage site and the first 8 amino acids of FabI, and replacing it with a linker encoding the first 8 amino acids of FabI plus a glycine residue between the initiator methionine and the lysine at position 2. This plasmid was called pET-*fabI*. The linker was made by annealing the following two oligonucleotides: 5'-
20 CATGGGCTTAAATCTTGAAAACAAAACA-3' and 5'-
TATGTTTTGTTTTCAAGATTAAAGCC-3'. The linker sequence in pET-*fabI* was confirmed by dideoxy sequencing. Only native FabI was used for compound evaluation. For overproduction of native FabI, plasmid pET-*fabI* was transformed into BL21(DE3) (Novagen) cells, to form strain BL21(DE3):pET-*fabI*.

Purification of *S. aureus* FabI

25 *S. aureus* FabI was expressed as soluble protein to 10% of total cell protein, 400g cells being recovered from 15L fermentation in tryptone phosphate medium. The cells
30 were lysed and the sample centrifuged. The resulting supernatant was filtered and purified using three consecutive chromatography columns: ion-exchange (Source 15Q), dye-affinity (Blue sepharose), and size exclusion chromatography columns (Superose 12). After each column the FabI containing fractions were pooled, concentrated, and checked for purity and biological activity.

Cloning of *E. coli* FabI:

A PCR fragment of correct size for *E. coli* FabI was PCR amplified from *E. coli* chromosomal DNA, subcloned into the TOPO TA cloning vector, and verified by colony
5 PCR + restriction endonuclease analysis. The presumptive *E. coli* FabI PCR fragment was subcloned into the expression vector pBluePet. The FabI clone was transformed into *E. coli* strain BL21(DE3). Small Scale expression studies show an over-expressed protein band of correct molecular weight (~28 Kda) for *E. coli* FabI clearly visible following
10 Coomassie staining of SDS PAGE gels. DNA sequencing of the *E. coli* FabI expression constructs illustrated that no errors were apparent. N' terminal amino acid sequencing has confirmed the over-expressed protein band to be *E. coli* FabI.

Purification of *E. coli* FabI

15 *E. coli* FabI was expressed as soluble protein to 15% of total cell protein; 120g cells being recovered from 3L fermentation in shake flasks in modified terrific broth. The cells were lysed and the sample centrifuged. The resulting supernatant was filtered and purified using three consecutive chromatography columns: ion-exchange (Source 15Q), dye-affinity (blue sepharose), and size exclusion (superose 12). After each column the FabI containing
20 fractions were pooled, concentrated and checked for purity and biological activity.

S. aureus FabI Enzyme Inhibition Assay (NADH):

Assays were carried out in half-area, 96-well microtitre plates. Compounds were
25 evaluated in 50-uL assay mixtures containing 100 mM NaADA, pH 6.5 (ADA = N-[2-acetamido]-2-iminodiacetic acid), 4 % glycerol, 0.25 mM crotonoyl CoA, 1 mM NADH, and an appropriate dilution of *S. aureus* FabI. Inhibitors were typically varied over the range of 0.01-10 uM. The consumption of NADH was monitored for 20 minutes at 30 °C
30 by following the change in absorbance at 340 nm. Initial velocities were estimated from an exponential fit of the non-linear progress curves represented by the slope of the tangent at t = 0 min. IC₅₀'s were estimated from a fit of the initial velocities to a standard, 4-parameter model and are typically reported as the mean ± S.D. of duplicate determinations. Triclosan, a commercial antibacterial agent and inhibitor of FabI, is currently included in all assays as a positive control. Compounds of this invention have IC₅₀'s from about 2.0 micromolar to
35 about 0.15 micromolar.

S. aureus FabI Enzyme Inhibition Assay (NADPH):

Assays were carried out in half-area, 96-well microtitre plates. Compounds were evaluated in 150-uL assay mixtures containing 100 mM NaADA, pH 6.5 (ADA = N-[2-acetamido]-2-iminodiacetic acid), 4 % glycerol, 0.25 mM crotonoyl CoA, 50 uM NADPH, and an appropriate dilution of *S. aureus* FabI. Inhibitors were typically varied over the range of 0.01-10 uM. The consumption of NADPH was monitored for 20 minutes at 30 °C by following the change in absorbance at 340 nm. Initial velocities were estimated from an exponential fit of the non-linear progress curves represented by the slope of the tangent at t = 0 min. IC₅₀'s were estimated from a fit of the initial velocities to a standard, 4-parameter model and are typically reported as the mean ± S.D. of duplicate determinations. Triclosan, a commercial antibacterial agent and inhibitor of FabI, is currently included in all assays as a positive control.

E. coli FabI Enzyme Inhibition Assay:

Assays were carried out in half-area, 96-well microtitre plates. Compounds were evaluated in 150-uL assay mixtures containing 100 mM NaADA, pH 6.5 (ADA = N-[2-acetamido]-2-iminodiacetic acid), 4 % glycerol, 0.25 mM crotonoyl CoA, 50 uM NADH, and an appropriate dilution of *E. coli* FabI. Inhibitors were typically varied over the range of 0.01-10 uM. The consumption of NADH was monitored for 20 minutes at 30 °C by following the change in absorbance at 340 nm. Initial velocities were estimated from an exponential fit of the non-linear progress curves represented by the slope of the tangent at t = 0 min. IC₅₀'s were estimated from a fit of the initial velocities to a standard, 4-parameter model and are typically reported as the mean ± S.D. of duplicate determinations. Triclosan, a commercial antibacterial agent and inhibitor of FabI, is currently included in all assays as a positive control. Compounds of this invention have IC₅₀'s from about 4.0 micromolar to about 0.15 micromolar.

Preparation and purification of crotonoyl-ACP:

Reactions contained 5 mg/mL *E. coli* apo-ACP, 0.8 mM crotonoyl-CoA (Fluka), 10 mM MgCl₂, and 30 uM *S. pneumoniae* ACP synthase in 50 mM NaHEPES, pH 7.5. The mixture was gently mixed on a magnetic stirrer at 23 °C for 2 hr, and the reaction was terminated by the addition of 15 mM EDTA. The reaction mixture was filtered through a 0.2 micron filter (Millipore) and applied to a MonoQ column (Pharmacia) equilibrated with 20 mM Tris-Cl, pH 7.5. The column was washed with buffer until all non-adherent

material was removed (as observed by UV detection), and the crotonoyl-ACP was eluted with a linear gradient of 0 to 400 mM NaCl.

S. aureus FabI Enzyme Inhibition Assay using crotonoyl-ACP:

5

Assays are carried out in half-area, 96-well microtitre plates. Compounds are evaluated in 150 uL assay mixtures containing 100 mM NaADA, pH 6.5 (ADA = N-(2-acetamido)-2-iminodiacetic acid), 4 % glycerol, 25 uM crotonoyl-ACP, 50 uM NADPH, and an appropriate dilution of *S. aureus* Fab I (approximately 20 nM). Inhibitors are typically varied over the range of 0.01-10 uM. The consumption of NADPH is monitored for 20 minutes at 30 °C by following the change in absorbance at 340 nm. Initial velocities are estimated from a linear fit of the progress curves. IC50's are estimated from a fit of the initial velocities to a standard, 4-parameter model (Equation 1) and are typically reported as the mean \pm S.D. of duplicate determinations. The apparent Ki is calculated from Equation 2 assuming the inhibition is competitive with crotonoyl-ACP.

15

Equation 1: $v = \text{Range}/(1+[I]/\text{IC}_{50}) + \text{Background}$

Equation 2: $K_i(\text{app}) = \text{IC}_{50}/(1+[S]/K_s)$

20

Antimicrobial Activity Assay:

Whole-cell antimicrobial activity was determined by broth microdilution using the National Committee for Clinical Laboratory Standards (NCCLS) recommended procedure, Document M7-A4, "Methods for Dilution Susceptibility Tests for Bacteria that Grow Aerobically". The compound was tested in serial two-fold dilutions ranging from 0.06 to 64 mcg/mL. Test organisms were selected from the following laboratory strains: *Staphylococcus aureus* Oxford, *Staphylococcus aureus* WCUH29, *Streptococcus pneumoniae* ERY2, *Streptococcus pneumoniae* 1629, *Streptococcus pneumoniae* N 1387, *Enterococcus faecalis* 1, *Enterococcus faecalis* 7, *Haemophilus influenzae* Q1, *Haemophilus influenzae* NEMC1, *Moraxella Catarrhalis* 1502, *Escherichia coli* 7623 AcrABEFD+, *Escherichia coli* 120 AcrAB-, *Escherichia coli* MG1655, *Escherichia coli* MG1658. The minimum inhibitory concentration (MIC) was determined as the lowest concentration of compound that inhibited visible growth. A mirror reader was used to assist in determining the MIC endpoint.

35

One skilled in the art would consider any compound with a MIC of less than 256 $\mu\text{g/mL}$ to be a potential lead compound. Preferably, the compounds used in the

antimicrobial assays of the present invention have a MIC value of less than 128 µg/mL. Most preferably, said compounds have a MIC value of less than 64 µg/mL.

5 The examples which follow are intended in no way to limit the scope of this invention, but are provided to illustrate how to make and use the compounds of this invention. Many other embodiments will be readily apparent to those skilled in the art.

EXAMPLES

10 General

Proton nuclear magnetic resonance (¹H NMR) spectra were recorded at 300 MHz, and chemical shifts are reported in parts per million (δ) downfield from the internal standard tetramethylsilane (TMS). Abbreviations for NMR data are as follows: s = singlet, 15 d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in Hertz. CDCl₃ is deuteriochloroform, DMSO-d₆ is hexadeuteriodimethylsulfoxide, and CD₃OD is tetradeuteriomethanol. Mass spectra were obtained using electrospray (ES) ionization techniques. Elemental analyses were performed by Quantitative Technologies 20 Inc., Whitehouse, NJ. Melting points were obtained on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius. Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Flash chromatography was carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel. Analytical HPLC was performed on Beckman chromatography 25 systems. Preparative HPLC was performed using Gilson chromatography systems. ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan. PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada. Celite® is a filter aid 30 composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.

Preparation 1Preparation of 1-methyl-2-(methylaminomethyl)indole

5 a) Ethyl 1-methylindole-2-carboxylate

NaH (60% dispersion in mineral oil, 8.0 g, 200.5 mmole) was washed with hexanes, then was suspended in dry DMF (530 mL). Solid ethyl indole-2-carboxylate (25.3 g, 133.7 mmole) was added portionwise over 5 - 10 min, allowing gas evolution to subside between additions. When the addition was complete, the yellow mixture was stirred for 15 min, then methyl iodide (42 mL, 668.3 mmole) was added all at once. The reaction was exothermic, and the internal temperature rose to 40 - 45°C. After 1 hr, the reaction was quenched with 10% NH₄Cl (100 mL) and concentrated on the rotavap (high vacuum). The residue was partitioned between Et₂O (500 mL) and H₂O (100 mL), and the layers were separated. The Et₂O layer was washed with H₂O (100 mL), dried (MgSO₄), and concentrated to leave the title compound (27.1 g, quantitative) as a light yellow solid. This was used without further purification: TLC (10% EtOAc/hexanes) R_f = 0.39.

b) N,1-Dimethylindole-2-carboxamide

A suspension of ethyl 1-methylindole-2-carboxylate (27.1 g, 133.3 mmole) in 40% aqueous CH₃NH₂ (300 mL) and MeOH (30 mL) was stirred at RT. A solid tended to gradually creep up the walls of the flask, and was washed down periodically with MeOH. The flask was tightly stoppered to keep the material inside the flask. As the reaction proceeded, the solid dissolved, but eventually the product began to precipitate. The reaction was stirred at RT for 3 days, then was concentrated to remove approximately 200 mL of the solvent. The remaining residue was diluted with H₂O (300 mL), and the solid was collected by suction filtration and washed with H₂O. Drying at 50 - 60°C in high vacuum left the title compound (23.4 g, 93%) as a faintly yellow solid: MS (ES) m/e 189 (M+H)⁺.

30 c) 1-Methyl-2-(methylaminomethyl)indole

A 3-liter 3-necked roundbottom flask equipped with overhead stirring was charged with N,1-dimethylindole-2-carboxamide (23.4 g, 124.6 mmole) and anhydrous THF (170 mL). The solution was stirred while a solution of LiAlH₄ in THF (1.0 M, 250 mL, 250 mmole) was added via syringe. Gas was evolved during the addition of the first 50 mL of LiAlH₄ solution. When the addition was complete, the resulting light yellow solution was heated at gentle reflux. After 24 hr, the reaction was cooled in ice and quenched by the sequential dropwise addition of H₂O (9.5 mL), 15% NaOH (9.5 mL), and H₂O (28.5 mL).

The mixture was stirred for 15 min, then was filtered through celite®, and the filter pad was washed thoroughly with THF. The filtrate was concentrated and the residue was flash chromatographed on silica gel (10% MeOH/CHCl₃ containing 5% conc. NH₄OH). The title compound (20.2 g, 93%) was obtained as a light yellow oil: MS (EI) m/e 175 (M+H)⁺.

5

Preparation 2

The preparation of 1-Methyl-3-(methylaminomethyl)indole

10 a) Ethyl 1-methylindole-3-carboxylate

According to the procedure of Preparation 1a, except substituting ethyl 3-indole acetate (25.3 g, 133.7 mmole) for ethyl indole-2-carboxylate, the title compound was prepared as a light yellow solid and used without further purification.

15 b) N,1-Dimethylindole-3-carboxamide

According to the procedure of Preparation 1b, except substituting ethyl 1-methylindole-3-carboxylate (27.1 g, 133.3 mmole) for ethyl 1-methylindole-2-carboxylate, the title compound (23.4 g, 93%) was prepared as a light yellow solid and used without further purification: MS (ES) m/e 189 (M+H)⁺.

20

c) 1-Methyl-3-(methylaminomethyl)indole

According to the procedure of Preparation 1c, except substituting N,1-dimethylindole-3-carboxamide (23.4 g, 124.6 mmole) for N,1-dimethylindole-2-carboxamide, the title compound (20.2 g, 93%) was prepared as a light yellow oil: MS (ES) m/e 175 (M+H)⁺.

25

Preparation 3

Preparation of 4-amino-3-[(N-methylacetyl amino)methyl]benzoic acid trifluoroacetate

30

a) *tert*-Butyl 3-methyl-4-nitro benzoate

To a pyridine solution of 3-methyl-4-nitrobenzoic acid (18.1 g, 100.0 mmole) at RT was added benzenesulfonyl chloride in one portion. After 10 min, anhydrous *t*-butanol (9.4 mL, 100.0 mmole) was added and the reaction solution was allowed to stir for 1 hr.

35 The resulting suspension was poured into ice-water (400 mL) and stirred vigorously for 1 hr. The light yellow suspension was filtered through a scinter-glass funnel washing with H₂O. The remaining yellow solids were dissolved in toluene (400 mL), dried over MgSO₄

and then filtered through a short column of silica gel washing with toluene. Concentration of the solution under vacuum (15 mm Hg) and drying on high vacuum afforded the title compound (22.5 g, 95%) as a light yellow solid: MS (ES) m/e 238 (M+H)⁺.

5 b) *tert*-Butyl 3-methylaminomethyl-4-nitro benzoate

To a stirred solution of *tert*-butyl 3-methyl-4-nitro benzoate (22.5 g, 94.9 mmole) in CH₂Cl₂ (450 mL) at RT contained in a 1L one-neck round bottom flask was added NBS (18.6 g, 104.4 mmole) and benzoyl peroxide (2.3 g, 9.5 mmole). The flask was equipped with a reflux condensor and a 150 watt tungsten-light source was shined on the reaction for 10 36 hrs. The reaction solution was washed with H₂O, dried over Na₂SO₄ and concentrated under vacuum. The resulting orange residue was dissolved in ethyl acetate and filtered through silica gel (EtOAc/hexanes, 1:4). Concentration on a rotary evaporator gave an orange oil which was used directly in the next step without further purification.

To the crude bromide in THF (150 mL) was added 40% aqueous CH₃NH₂ (50 mL) 15 in one portion at RT. After 18 hr, the reaction solution was concentrated to remove the THF. The resulting aqueous solution was extracted with EtOAc (2 x 200 mL) and the combined organic phases were sequentially washed with H₂O and brine. Drying over K₂CO₃ and concentration gave a yellow oil which was purified on silica (hexanes/EtOAc, 1:1) to afford the title compound (19.2 g, 76%) as a light yellow solid: MS (ES) m/e 267 20 (M+H)⁺.

c) *tert*-Butyl-4-amino-3-[(N-methylacetylamino)methyl]benzoate

To a stirred solution of *t*-butyl 3-(methylaminomethyl)-4-nitro benzoate (2.4 g, 9.0 mmole) in CH₂Cl₂ at RT was added Et₃N (2.52 mL, 18.0 mmole) and acetic anhydride 25 (1.8 g, 18.0 mmole). After 12 hrs, the reaction solution was concentrated under vacuum, dissolved in EtOAc (150 mL) and washed with H₂O. The EtOAc solution was dried over Na₂SO₄ and concentrated under vacuum to a yellow oil. The oil was further dried under high vacuum and used directly in the next procedure.

The crude product was dissolved in EtOAc (50 mL) and CH₃OH (50 mL) and 30 placed in a Parr hydrogenation flask. A catalytic amount of 10% Pd/C was added to the reaction solution and the contents were placed on a Parr shaker under H₂ (50 psi) and shaken for 4 hours. The solution was filtered through celite and concentrated under vacuum. Purification on silica (hexanes/EtOAc, 1:1) afforded the title compound (2.13 g, 85% over two steps) as an off-white solid: MS (ES) m/e 279 (M+H)⁺.

35

d) 4-amino-3-[(N-methylacetylamino)methyl]benzoic acid trifluoroacetate salt

To a solution of *t*-butyl 4-amino-3-[(N-methylacetylamino)methyl] benzoate (2.13 g, 7.65 mmole) in CH₂Cl₂ (150 mL) at RT was added TFA (30 mL). After 12 hr, the reaction solution was concentrated to an oil and dried under high vacuum overnight. The resulting residue was washed with hexanes and Et₂O to afford the title compound (2.56 g, 7.60 mmole) as an off-white solid. This compound was used without further purification: MS (ES) *m/e* 223 (M+H-TFA)⁺.

Preparation 4

Preparation of 4-amino-3-[(N-phenethylacetylamino)methyl]benzoic acid

a) *tert*-Butyl 4-nitro-3-(phenethylamino)methyl benzoate

Crude *tert*-butyl 3-bromomethyl-4-nitrobenzoate (from Preparation 3b) was dissolved in dry THF (50 mL), and solid NaHCO₃ (2.52 g, 30 mmole) was added. The mixture was stirred briskly, and phenethylamine (3.8 mL, 30 mmole) was added. The color of the solution darkened slightly to a deeper yellow. Within several minutes, the mixture had become very cloudy. After 4 hr, the reaction was concentrated and the residue was partitioned between H₂O (50 mL) and Et₂O (100 mL). The layers were separated, and the aqueous layer was extracted with Et₂O (2 x 100 mL). The organic layers were combined, dried (MgSO₄), and concentrated to a yellow oil. Flash chromatography on silica gel (20 % EtOAc/hexanes) gave the title compound (2.86 g, 40 % for two steps) as a yellow oil: ¹H NMR (250 MHz, CDCl₃) δ 8.19 (d, *J* = 1.7 Hz, 1 H), 7.98 (dd, *J* = 8.4, 1.7 Hz, 1 H), 7.90 (d, *J* = 8.4 Hz, 1 H), 7.10 - 7.40 (m, 5 H), 4.06 (s, 2 H), 2.75 - 3.00 (m, 4 H), 1.61 (s, 9 H); MS (ES) *m/e* 357 (M + H)⁺.

b) *tert*-Butyl 3-[N-(*tert*-butoxycarbonyl)-N-phenethylamino]methyl-4-nitrobenzoate

Di-*tert*-butyl dicarbonate (2.10 g, 9.62 mmole) was added all at once to a solution of *tert*-butyl 3-(phenethylamino)methyl-4-nitrobenzoate (2.86 g, 8.02 mmole) in CHCl₃ (30 mL) at RT. The reaction was stirred at RT for 2.5 hr, then at reflux for 0.5 hr. Concentration and flash chromatography on silica gel (15 % EtOAc/hexanes) gave the title compound (3.70 g, quantitative) as a yellow oil: ¹H NMR (250 MHz, CDCl₃) δ 7.85 - 8.10 (m, 3 H), 7.05 - 7.40 (m, 5 H), 4.55 - 4.85 (m, 2 H), 3.35 - 3.60 (m, 2 H), 2.75 - 3.00 (m, 2 H), 1.20 - 1.80 (m, 18 H); MS (ES) *m/e* 479 (M + Na)⁺, 457 (M + H)⁺.

c) *tert*-Butyl 4-amino-3-[[N-(*tert*-butoxycarbonyl)-N-phenethylamino]methyl]benzoate

A mixture of *tert*-butyl 3-[[N-(*tert*-butoxycarbonyl)-N-phenethylamino]methyl]-4-nitrobenzoate (2.7 g, 5.8 mmole), 10 % Pd/C (0.6 g, 0.6 mmole Pd), and EtOAc (60 mL) was shaken under H₂ (50 psi). After 3 hr, the mixture was filtered to remove the catalyst, and the filtrate was concentrated to dryness. Flash chromatography on silica gel (20% EtOAc/hexanes) gave the title compound (2.3 g, 91 %) as a yellow foamy oil which slowly partially solidified: ¹H NMR (250 MHz, CDCl₃) δ 7.74 (dd, J = 8.4, 2.0 Hz, 1 H), 7.67 (d, J = 2.0 Hz, 1 H), 7.05 - 7.40 (m, 5 H), 6.57 (d, J = 8.4 Hz, 1 H), 5.00 (br s, 2 H), 4.30 (s, 2 H), 3.32 (app. t, 2 H), 2.69 (app. t, 2 H), 1.59 (s, 9 H), 1.46 (s, 9 H); MS (ES) *m/e* 449.2 (M + Na)⁺, 427.2 (M + H)⁺.

d) 4-amino-3-[N-phenethylaminomethyl]benzoate trifluoroacetate salt

To a solution of *tert*-butyl 4-amino-3-[[N-(*tert*-butoxycarbonyl)-N-phenethylamino]methyl]benzoate (2.3 g, 5.4 mmole) in CH₂Cl₂ (100 mL) at RT was added TFA (25 mL). After 12 hr, the reaction solution was concentrated to an oil and the residue dried under high vacuum overnight. The resulting residue was washed with hexanes and diethyl ether to afford the title compound (2.7 g, 5.4 mmole) as an off-white solid: MS (ES) *m/e* 271 (M+H-2TFA)⁺.

e) 4-amino-3-[(N-phenethylacetylaminomethyl)benzoic acid

To a stirred solution of 4-amino-3-[N-phenethylaminomethyl]benzoate bis-trifluoroacetate salt (1.0 g, 2.0 mmole) in CH₂Cl₂ at RT was added Et₃N (1.1 mL, 7.9 mmole) and acetic anhydride (0.26 g, 2.6 mmole). After 12 hr, the reaction solution was concentrated under vacuum, dissolved in 1M NaOH (15mL), and washed with hexanes. The aqueous solution was neutralized with 1M HCl and extracted with EtOAc (2 x 50 mL). The EtOAc solution was dried over Na₂SO₄ and concentrated to an off-white solid which was used without further purification: MS (ES) *m/e* 313 (M+H)⁺.

Preparation 5

30

Preparation of *tert*-Butyl 4-amino-3-[(N-methyl)aminomethyl] benzoate

A solution of *t*-butyl-3-[N-(methyl)aminomethyl]-4-nitro-benzoate (12.0 g, 45.1 mmole), from procedure 3a, in CH₃OH (50 mL) was placed in a Parr hydrogenation flask. Approximately (0.50g) of 10% Pd/C was added to the reaction solution and the contents were shaken on a Parr shaker under H₂ (50 psi) for 4 hours. The suspension was filtered through celite and concentrated under vacuum. Washing of the resulting residue with Et₂O

afforded a viscous light yellow oil which was used without further purification: MS (ES) m/e 237 (M+H)⁺.

Preparation 6

5

Preparation of 4-amino-3-[(2-hydroxy-4,N-dimethylpentanoylamino)methyl]benzoic acid trifluoroacetate

a) *tert*-Butyl 4-amino-3-[(2-hydroxy-4,N-dimethylpentanoylamino)methyl]benzoic acid
10 To a stirred solution of *t*-butyl 3-[N-(methyl)aminomethyl]-4-amino benzoate (2.6 g, 11.0 mmole) in DMF (20 mL) at RT was added diisopropylethyl amine (2.9 mL, 16.9 mmole), HOBt (2.3 g, 16.9 mmole) 2-hydroxy-4-methylpentanoic acid (2.04 g, 15.15 mmole) and finally EDC (3.24 g, 16.9 mmole). After 12 hr, the reaction contents were poured onto H₂O (200 mL) and extracted with EtOAc (2 x 150 mL). The organic phases
15 were combined and sequentially washed with H₂O (100 mL) and brine. Drying over Na₂SO₄ and purification on silica (CHCl₃/CH₃OH, 95:5) afforded the title compound (3.50 g, 91%) as a light yellow oil: MS (ES) m/e 351 (M+H)⁺.

b) 4-Amino-3-[(2-hydroxy-4,N-dimethylpentanoylamino)methyl]benzoic acid
20 trifluoroacetate
To a stirred solution of *t*-butyl 4-amino-3-[(2-hydroxy-4,N-dimethylpentanoylamino)methyl]benzoic acid (3.50 g, 10.0 mmole) in CH₂Cl₂ (20 mL) at RT was added TFA (20 mL). After 12 hr, the reaction contents were evaporated, washed with hexanes and dried under high vacuum overnight affording the title compound as an
25 orange oil (4.42 g, 10.8 mmol). This product was used without further purification: MS (ES) m/e 295 (M+H-TFA)⁺.

Preparation 7

30 Preparation of 4-amino-3-[(ethoxy-N-methylcarbonylamino)methyl]benzoic acid trifluoroacetate

a) *tert*-Butyl 4-amino-3-[(ethoxy-N-methylcarbonylamino)methyl]benzoate
To a stirred solution of *t*-butyl 3-[N-(methyl)aminomethyl]-4-amino benzoate
35 (2.51 g, 10.63 mmole) in CH₂Cl₂ (20 mL) at 0 °C was added triethyl amine (1.63 mL, 11.7 mmole), and ethylchloroformate (1.15 g, 10.63 mmole). The reaction solution was allowed to warm to RT overnight. The reaction contents were concentrated under vacuum and

partition between H₂O (100 mL) and EtOAc (200 mL). The organic phase was combined washed sequentially with H₂O (100 mL) and brine. Drying over Na₂SO₄ and purification on silica (CHCl₃/CH₃OH, 95:5) afforded the title compound (2.98 g, 91%) as a light yellow oil: MS (ES) m/e 309 (M+H)⁺.

5

b) 4-amino-3-[(ethoxy-N-methylcarbonylamino)methyl]benzoic acid trifluoro acetate

To a stirred solution of *t*-butyl-4-amino-3-[(2-hydroxy-4,N-dimethylpentanoylamino)methyl]benzoic acid (2.98 g, 9.67 mmole) in CH₂Cl₂ (20 mL) at RT was added TFA (20 mL). After 12 hr, the reaction contents were concentrated, washed with hexanes and dried under high vacuum overnight affording the title compound as an orange oil (3.51 g, 9.60 mmol). This product was used without further purification: MS (ES) m/e 253 (M+H-TFA)⁺.

10

Preparation 8

15

Preparation of 4-amino-3-[(2-hydroxy-N-methylacetylaminomethyl]benzoic acid

a) *tert*-Butyl 4-nitro-3-[(2-hydroxy-N-methylacetylaminomethyl]benzoate

To a stirred solution of *t*-butyl-3-[N-(methyl)aminomethyl]-4-amino benzoate (7.0 g, 26.3 mmole) in DMF (30 mL) at RT was added diisopropylethyl amine (5.0 mL, 28.9 mmole), HOBT (3.90 g, 28.9 mmole), 2-hydroxyacetic acid (2.2 g, 28.9 mmole) and finally EDC (5.54 g, 28.9 mmole). After 12 hr, the reaction contents were poured onto H₂O (200 mL) and extracted with EtOAc (2 x 150 mL). The organic phases were combined and sequentially washed with H₂O (100 mL) and brine. Drying over Na₂SO₄ and purification on silica (CHCl₃/CH₃OH, 95:5) afforded the title compound (7.92 g, 93%) as a light yellow oil: MS (ES) m/e 325 (M+H)⁺.

25

b) *tert*-Butyl 4-amino-3-[(2-hydroxy-N-methylacetylaminomethyl]benzoate

To a solution of *t*-butyl-4-nitro-3-[(2-hydroxy-N-methylacetylaminomethyl]benzoate (7.92 g, 23.15 mmole) in CH₃OH (25 mL) and EtOAc (25 mL) in a Parr hydrogenation flask was added 10% Pd/C (0.20 g). The contents were shaken on a Parr shaker under H₂ (50 psi) for 4 hours. The suspension was filtered through celite, concentrated under vacuum and washed with Et₂O to afford the title compound as a light orange foam which was used without further purification: MS (ES) m/e 295 (M+H)⁺.

35

Preparation 9

Preparation of 4-amino-3-[(2-hydroxy-3-indol-3-yl-N-methylpropanoylamino)methyl]benzoic acid trifluoro acetate

5

a) *tert*-Butyl 4-amino-3-[(2-hydroxy-3-indol-3-yl-N-methylpropanoylamino)methyl]benzoic acid

To a stirred solution of *t*-butyl-3-[N-(methyl)aminomethyl]-4-amino benzoate (0.60 g, 2.52 mmole), from Procedure 5, in DMF (20 mL) at RT was added diisopropylethyl amine (0.88 mL, 5.03 mmole), HOBt (0.37 g, 2.77 mmole), DL-3-indolelactic acid (0.57 g, 2.77 mmole) and finally EDC (0.53 g, 2.77 mmole). After 12 hr, the reaction contents were poured onto H₂O (100 mL) and extracted with EtOAc (2 x 100 mL). The organic phases were combined and sequentially washed with H₂O (100 mL) and brine. Drying over Na₂SO₄ and purification on silica (CHCl₃/CH₃OH, 95:5) afforded the title compound (0.99 g, 93%) as a light yellow oil: MS (ES) m/e 425 (M+H)⁺.

15

b) 4-Amino-3-[(2-hydroxy-3-indol-3-yl-N-methylpropanoylamino)methyl]benzoic acid trifluoro acetate

To a stirred solution of *t*-butyl-4-amino-3-[(2-hydroxy-3-indol-3-yl-N-methylpropanoylamino)methyl]benzoic acid (0.99 g, 2.34 mmole) in CH₂Cl₂ (20 mL) at RT was added TFA (20 mL). After 12 hr, the reaction contents were evaporated, washed with Et₂O and dried under high vacuum overnight affording the title compound (0.86 g, 2.34 mmol) as a pink solid. This product was used without further purification: MS (ES) m/e 369 (M+H-TFA)⁺.

25

Preparation 10

Preparation of 4-amino-3-[(2-cyclopentyl-N-methylacetylaminomethyl]benzoic acid trifluoro acetate

30

a) *tert*-Butyl 4-amino-3-[(2-cyclopentyl-N-methylacetylaminomethyl]benzoic acid

To a stirred solution of *t*-butyl-3-[N-(methyl)aminomethyl]-4-amino benzoate (0.55 g, 2.32 mmole), from Procedure 5, in DMF (20 mL) at RT was added diisopropylethyl amine (0.81 mL, 4.64 mmole), HOBt (0.34 g, 2.55 mmole), cyclopentane acetic acid (0.33 g, 2.55 mmole) and finally EDC (0.49 g, 2.55 mmole). After 12 hr, the reaction contents were poured onto H₂O (100 mL) and extracted with EtOAc (2 x 100 mL). The organic phases were combined and sequentially washed with H₂O (100 mL) and brine.

35

Drying over Na_2SO_4 and purification on silica ($\text{CHCl}_3/\text{CH}_3\text{OH}$, 95:5) afforded the title compound (0.75 g, 94%) as a light yellow oil: MS (ES) m/e 348 ($\text{M}+\text{H}$)⁺.

b) 4-Amino-3-[(2-cyclopentyl-N-methylacetyl-amino)methyl]benzoic acid trifluoro acetate

- 5 To a stirred solution of *t*-butyl-4-amino-3-[(2-cyclopentyl-N-methylacetyl-amino)methyl]benzoic acid (0.75 g, 2.16 mmole) in CH_2Cl_2 (20 mL) at RT was added TFA (20 mL). After 12 hr, the reaction contents were evaporated, washed with hexanes and dried under high vacuum overnight affording the title compound (0.63 g, 2.16 mmol) as an orange oil. This product was used without further purification: MS (ES) m/e 292 ($\text{M}+\text{H}-\text{TFA}$)⁺.
- 10

Preparation 11

- Preparation of 4-amino-3-[(methylamino)methyl]phenyl-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide
- 15

a) *t*-Butyl-4-nitro-3-[(N-methyl(phenylmethoxy)carbonylamino)methyl]benzoate

- To a stirred solution of *t*-butyl-3-[N-(methyl)aminomethyl]-4-nitro benzoate (11.97 g, 45.0 mmole), from Procedure 3b, in DMF (100 mL) at RT was added triethyl amine (7.27 mL, 52.2 mmole), and N-(benzyloxycarbonyloxy)succinamide (13.0 g, 52.2 mmole). After 12 hr, the reaction contents were poured onto H_2O (200 mL) and extracted with EtOAc (2 x 200 mL). The organic phases were combined and sequentially washed with H_2O (100 mL) and brine. Drying over Na_2SO_4 and purification on silica (hexanes/EtOAc, 1:1) afforded the title compound (17.46 g, 96%) as a light yellow oil: MS (ES) m/e 401 ($\text{M}+\text{H}$)⁺.
- 20
- 25

b) 4-nitro-3-[(N-methyl(phenylmethoxy)carbonylamino)methyl]benzoic acid

- To a stirred solution of *t*-butyl-4-nitro-3-[(N-methyl(phenylmethoxy)carbonylamino)methyl]benzoate (17.46 g, 43.65 mmole) in CH_2Cl_2 (100 mL) at RT was added TFA (50 mL). After 12 hr, the reaction contents were evaporated, washed with hexanes and dried under high vacuum overnight to afford the title compound (14.62 g, 42.5 mmol) as an orange oil. This product was used without further purification: MS (ES) m/e 345 ($\text{M}+\text{H}$)⁺.
- 30

- c) N-[(2-nitro-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-methyl(phenylmethoxy)carboxamide

To a stirred solution of 4-nitro-3-[[N-methyl(phenylmethoxy)carbonylamino]methyl]benzoic acid (4.56 g, 13.26 mmole) in DMF (20 mL) at RT was added diisopropylethyl amine (2.31 mL, 13.26 mmole), HOBt (1.79 g, 13.26 mmole), 1-methyl-2-(methylaminomethyl)indole (2.1 g, 12.0 mmole) and finally EDC (2.54 g, 13.26 mmole). After 12 hr, the reaction contents were poured onto H₂O (100 mL) and extracted with EtOAc (2 x 100 mL). The organic phases were combined and sequentially washed with H₂O (100 mL) and brine. Drying over Na₂SO₄ and purification on silica (hexanes/EtOAc, 1:1) afforded the title compound (5.52 g, 92%) as a viscous yellow oil: MS (ES) m/e 501 (M+H)⁺.

- d) 4-amino-3-[(methylamino)methyl]phenyl)-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide

To a solution of N-[(2-nitro-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-methyl(phenylmethoxy)carboxamide (6.1 g, 12.2 mmole) in CH₃OH (50 mL) contained in a Parr hydrogenation flask was added a 0.75 g of 10% Pd/C. The contents were shaken on a Parr shaker under H₂ (50 psi) for 6 hours. The suspension was filtered through celite and concentrated under vacuum. Purification on silica [CHCl₃/CH₃OH (containing 5% NH₄OH), 9:1] afforded the title compound (3.40 g, 83 %) as a viscous yellow oil: MS (ES) m/e 337 (M+H)⁺.

The following examples illustrate methods for preparing the biologically active compounds of this invention from intermediate compounds such as those described in the foregoing Preparations.

Example 1

Preparation of N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-phenylacetamide

- a) *tert*-Butyl 3-[(phenylamino)methyl]-4-nitro benzoate

To a solution of the crude *t*-butyl-3-bromomethyl-4-nitro benzoate (2.0 g, 6.3 mmole), from Procedure 3b, in THF (25 mL) at RT was added aniline (2.0 mL, 21.9 mmole). The reaction contents were concentrated, dissolved in EtOAc and washed sequentially with 10% aqueous NaHCO₃ and brine. Purification on silica afforded the title compound (1.95 g, 94%) as an orange solid: MS (ES) m/e 429 (M+H)⁺.

b) 3-[(phenylamino)methyl]phenyl-4-nitro-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide

To a stirred solution of *tert*-butyl 3-[(phenylamino)methyl]-4-nitro benzoate (1.95 g, 4.55 mmole) in CH₂Cl₂ (20 mL) at RT was added TFA (20 mL). After 12 hr, the reaction contents were concentrated, treated with 4M aqueous HCl, dioxane (10 mL) and concentrated under vacuum affording a tan solid. The solid residue was washed with hexanes and dried under high vacuum. This product was used directly in the next step without further purification.

To a stirred solution of the above compound in DMF (30 mL) at RT was added diethyl amine (1.7 mL, 12.1 mmole), 1-methyl-2-(methylaminomethyl)indole (1.0 g, 6.0 mmole), HOBt (0.81 g, 6.0 mmole) and finally EDC (1.15 g, 6.0 mmole). After 12 hr, the reaction contents were poured onto H₂O (100 mL) and extracted with EtOAc (2 x 100 mL). The organic phases were combined and sequentially washed with H₂O (100 mL) and brine. Drying over Na₂SO₄ and purification on silica (EtOAc) afforded the title compound (2.33 g, 92%) as a solid yellow foam: MS (ES) m/e 429 (M+H)⁺.

c) N-[(2-nitro-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-phenylacetamide

To a solution of 3-[(phenylamino)methyl]phenyl-4-nitro-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide (0.75 g, 1.8 mmole) in CHCl₃ (10 mL) at 45 °C was added acetic anhydride (0.38 mL, 4.2 mmole) followed by pyridine (0.30 mL, 3.8 mmole). After 12 hr, the reaction solution was concentrated under vacuum, dissolved in EtOAc and sequentially washed with 1 M HCl, and brine. Drying over Na₂SO₄ and purification on silica (EtOAc) afforded the title compound (0.82 g, 92%) as a yellow foam: MS (ES) m/e 493 (M+Na)⁺.

d) N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-phenylacetamide

To a solution of N-[(2-nitro-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-phenylacetamide (0.82 g, 1.7 mmole) in CH₃OH (50 mL) in a Parr hydrogenation flask was added 10% Pd/C (0.50 g). The contents were shaken on a Parr shaker under H₂ (50 psi) for 4 hours. The reaction suspension was filtered through celite and concentrated under vacuum. Purification on silica (CHCl₃/CH₃OH, 95:5) afforded the title compound (0.51 g, 68%) as an off-white solid: MS (ES) m/e 441 (M+H)⁺.

Example 2Preparation of N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-methylacetamide

5

To a stirred solution of 4-amino-3-[(N-methylacetylamino)methyl]benzoic acid trifluoro acetate (0.73 g, 2.17 mmole), from Procedure 3, in DMF (20 mL) at RT was added diisopropylethyl amine (0.83 mL, 4.78 mmole), HOBt (0.32 g, 2.39 mmole), 1-methyl-2-(methylaminomethyl)indole (0.40 g, 2.39 mmole) and finally EDC (0.45 g, 2.39 mmole). After 12 hr, the reaction contents were poured onto H₂O (100 mL) and extracted with EtOAc (2 x 100 mL). The organic phases were combined and sequentially washed with H₂O (100 mL) and brine. Drying over Na₂SO₄ and purification on silica (CHCl₃/CH₃OH, 95:5) afforded the title compound (0.73 g, 89%) as a light yellow solid: MS (ES) m/e 379 (M+H)⁺.

15

Example 3Preparation of N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-(2-phenylethyl)acetamide

20

According to the procedure of Example 2, except substituting 4-amino-3-[(N-phenethylacetylamino)methyl]benzoic acid (0.60 g, 1.92 mmole) for 4-amino-3-[(N-methylacetylamino)methyl]benzoic acid trifluoro acetate, the title compound (0.83 g, 92 %) was prepared as a yellow solid following chromatography on silica gel (CHCl₃/CH₃OH, 95:5): MS (ES) m/e 469 (M+H)⁺.

25

Example 4Preparation of N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-hydroxy-4-methyl-N-methylpentanamide

30

According to the procedure of Example 2, except substituting 4-amino-3-[(2-hydroxy-4,N-dimethylpentanoylamino)methyl]benzoic acid trifluoro acetate (2.1 g, 5.1 mmole) for 4-amino-3-[(N-methylacetylamino)methyl]benzoic acid trifluoro acetate, the title compound (2.06 g, 90 %) was prepared as a yellow foam following chromatography on silica gel (CHCl₃/CH₃OH, 95:5): MS (ES) m/e 451 (M+H)⁺.

35

Example 5Preparation of 4-amino-3-[(ethoxy-N-methylcarbonylamino)methyl]phenyl)-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide

5

According to the procedure of Example 2, except substituting 4-amino-3-[(ethoxy-N-methylcarbonylamino)methyl]benzoic acid trifluoro acetate (0.75 g, 2.05 mmole) for 4-amino-3-[(N-methylacetylaminomethyl]benzoic acid trifluoro acetate, the title compound (0.75 g, 90 %) was prepared as a tan foam following chromatography on silica gel (CHCl₃/CH₃OH, 95:5): MS (ES) *m/e* 409 (M+H)⁺.

10

Example 6Preparation of N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-hydroxy-N-methylacetamide

15

According to the procedure of Example 2, except substituting 4-amino-3-[(2-hydroxy-N-methylacetylaminomethyl]benzoic acid (1.0 g, 2.84 mmole) for 4-amino-3-[(N-methylacetylaminomethyl]benzoic acid trifluoro acetate, the title compound (0.99 g, 88 %) was prepared as an off-white solid following chromatography on silica gel (CHCl₃/CH₃OH, 95:5): MS (ES) *m/e* 395 (M+H)⁺.

20

Example 7Preparation of N-[(2-amino-5-{N-methyl-N-[(1-methylindol-3-yl)methyl]carbamoyl}phenyl)methyl]-N-methylacetamide

25

According to the procedure of Example 2, except substituting 4-amino-3-[(N-methylacetylaminomethyl]benzoic acid trifluoroacetate (0.44 g, 1.31 mmole) for 4-amino-3-[(N-methylacetylaminomethyl]benzoic acid trifluoro acetate, the title compound (0.45 g, 92 %) was prepared as an off-white solid following chromatography on silica gel (CHCl₃/CH₃OH, 95:5): MS (ES) *m/e* 379 (M+H)⁺.

30

Example 8Preparation of N-[(2-amino-5-[(N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl]phenyl)methyl]-2-hydroxy-3-indol-3-yl-N-methylpropanamide

5

According to the procedure of Example 2, except substituting 4-amino-3-[(2-hydroxy-3-indol-3-yl-N-methylpropanoylamino)methyl]benzoic acid trifluoro acetate (0.41 g, 1.12 mmole) for 4-amino-3-[(N-methylacetylaminomethyl]benzoic acid trifluoro acetate, the title compound (0.46 g, 78 %) was prepared as an off-white solid following chromatography on silica gel (CHCl₃/CH₃OH, 95:5): MS (ES) *m/e* 524 (M+H)⁺.

10

Example 9Preparation of N-[(2-amino-5-[(N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl]phenyl)methyl]-2-cyclopentyl-N-methylacetamide

15

According to the procedure of Example 2, except substituting 4-amino-3-[(2-cyclopentyl-N-methylacetylaminomethyl]benzoic acid trifluoro acetate (1.05 g, 3.60 mmole) for 4-amino-3-[(N-methylacetylaminomethyl]benzoic acid trifluoro acetate, the title compound (1.45 g, 90 %) was prepared as an off-white solid following chromatography on silica gel (hexanes/EtOAc, 1:2): MS (ES) *m/e* 448 (M+H)⁺.

20

Example 10Preparation of {4-amino-3-[(4-hydroxyphenyl)-N-methylcarbonylamino]methyl}phenyl-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide

25

According to the procedure of Example 2, except substituting 4-hydroxybenzoic acid (0.23 g, 1.64 mmole) for 4-amino-3-[(N-methylacetylaminomethyl]benzoic acid trifluoro acetate and substituting {4-amino-3-[(methylaminomethyl]phenyl)-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide (0.50 g, 1.49 mmole) for 1-methyl-2-(methylaminomethyl)indole, the title compound (0.62 g, 92 %) was prepared as an off-white solid following chromatography on silica gel (CHCl₃/CH₃OH, 95:5): MS (ES) *m/e* 457 (M+H)⁺.

30

35

Example 11

Preparation of N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-methyl-3-(phenylsulfonyl)propanamide

5

According to the procedure of Example 2, except substituting 3-(phenylsulfonyl)propionic acid (0.35 g, 1.64 mmole) for 4-amino-3-[(N-methylacetyl amino)methyl]benzoic acid trifluoro acetate and substituting {4-amino-3-[(methylaminomethyl)phenyl]-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide (0.50 g, 1.49 mmole) for 1-methyl-2-(methylaminomethyl)indole, the title compound (0.72 g, 91 %) was prepared as an off-white solid following chromatography on silica gel (CHCl₃/CH₃OH, 95:5): MS (ES) *m/e* 533 (M+H)⁺.

10

Example 12

15

Parenteral Dosage Unit Composition

A preparation which contains 20 mg of the compound of Example 1 as a sterile dry powder is prepared as follows: 20 mg of the compound is dissolved in 15 mL of distilled water. The solution is filtered under sterile conditions into a 25 mL multi-dose ampoule and lyophilized. The powder is reconstituted by addition of 20 mL of 5% dextrose in water (D5W) for intravenous or intramuscular injection. The dosage is thereby determined by the injection volume. Subsequent dilution may be made by addition of a metered volume of this dosage unit to another volume of D5W for injection, or a metered dose may be added to another mechanism for dispensing the drug, as in a bottle or bag for IV drip infusion or other injection-infusion system.

20

25

Example 13

Oral Dosage Unit Composition

30

A capsule for oral administration is prepared by mixing and milling 50 mg of the compound of Example 1 with 75 mg of lactose and 5 mg of magnesium stearate. The resulting powder is screened and filled into a hard gelatin capsule.


35

Example 14Oral Dosage Unit Composition

- 5 A tablet for oral administration is prepared by mixing and granulating 20 mg of sucrose, 150 mg of calcium sulfate dihydrate and 50 mg of the compound of Example 1 with a 10% gelatin solution. The wet granules are screened, dried, mixed with 10 mg starch, 5 mg talc and 3 mg stearic acid; and compressed into a tablet.
- 10 The above description fully discloses how to make and use the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprises the state of the art and are incorporated herein by reference as though
- 15 fully set forth.

What is claimed is:

1. A compound according to formula (I):



wherein:

R^1 is C_{1-4} alkyl;

R^2 is C_{1-4} alkyl;

10 R^3 is $-C_{1-4}$ alkyl, $-C_{0-4}$ alkyl-Ar or $-C_{0-4}$ alkyl-Het;

R^4 is $-C_{1-4}$ alkyl, $-(CH_2)_{1-4}OH$, $-OC_{1-4}$ alkyl, $-SC_{1-4}$ alkyl, $-N(C_{1-4}alkyl)_2$, $-C_{0-4}$ alkyl-Ar, $-C_{0-4}$ alkyl-Het, $-C_{0-4}$ alkyl- C_{3-6} cycloalkyl, $-CH(OH)-CH_2-R^*$ or $-(CH_2)_{1-3}SO_2Ar$;

R^* is C_{1-4} alkyl, Ar or Het;

15 X is H, C_{1-4} alkyl, OR, SR, CN, $N(R')_2$, $CH_2N(R')_2$, NO_2 , CF_3 , CO_2R' ,


$CON(R')_2$, COR, $NRC(O)R'$, F, Cl, Br, I, or $-S(O)_rCF_3$;

R' is H, C_{1-6} alkyl or $-C_{0-6}$ alkyl-Ar; and

r is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 of formula (Ia):



(Ia).

3. A compound according to claim 1 in which R^3 is $-C_{1-4}$ alkyl or $-C_{0-2}$ alkyl-Ph.

4. A compound according to claim 1 in which R⁴ is -C₁₋₄alkyl, -CH₂OH, -OC₁₋₄alkyl, -C₀₋₂alkyl-Ph, -C₀₋₂alkyl-C₃₋₆cycloalkyl, -CH(OH)-CH₂-R* or -(CH₂)₂SO₂Ph.

5. A compound according to claim 1 which is:

N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-methylacetamide;

N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-(2-phenylethyl)acetamide;

10 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-hydroxy-4-methyl-N-methylpentanamide;

[4-amino-3-[(ethoxy-N-methylcarbonylamino)methyl]phenyl]-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide;

15 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-hydroxy-N-methylacetamide;

N-[(2-amino-5-{N-methyl-N-[(1-methylindol-3-yl)methyl]carbamoyl}phenyl)methyl]-N-methylacetamide;

N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-phenylacetamide;

20 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-hydroxy-3-indol-3-yl-N-methylpropanamide;

[4-amino-3-[[4-hydroxyphenyl]-N-methylcarbonylamino]methyl]phenyl)-N-methyl-N-[(1-methylindol-2-yl)methyl]carboxamide;

25 N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-N-methyl-3-(phenylsulfonyl)propanamide; or

N-[(2-amino-5-{N-methyl-N-[(1-methylindol-2-yl)methyl]carbamoyl}phenyl)methyl]-2-cyclopentyl-N-methylacetamide;

or a pharmaceutically acceptable salt thereof.

30 6. A pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier.

7. A method for inhibiting Fab I which comprises administering to a subject in need thereof a compound according to claim 1.

35


8. A method of treating bacterial infections which comprises administering to a subject in need thereof a compound according to claim 1.

9. A compound according to any one of claims 1 to 6 for use as a medicament.


5 10. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of bacterial infections.

11. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of diseases in which inhibition of Fab I is
10 indicated.

12. A process for preparing compounds of formula (I) as defined in claim 1, which process comprises reacting a compound of formula (II) with a compound of formula (III):



(II)



(III)

wherein R¹, R², R³, R⁴ and X are as defined in formula (I), with any reactive functional groups protected, in the presence of EDC and HOBT;

and thereafter removing any protecting groups, and optionally forming a
20 pharmaceutically acceptable salt.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/27591

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/404; C07D 209/14

US CL : 514/419; 548/496

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/419; 548/496

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,932,743 A (COLLINI et al) 03 August 1999, (03.08.1999).	1-6, 9

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 09 December 2000 (09.12.2000)	Date of mailing of the international search report 29 JAN 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer Fiona T. Powers Telephone No. 703-308-1235

Form PCT/ISA/210 (second sheet) (July 1998)